AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

News

Author: Parkinson's Life editorsPublished: 31 August 2017

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

AstraZeneca and Takeda lead

AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after agreeing a deal to co-develop an early-stage medicine for Parkinson’s disease.

The drug, MEDI1341, is an antibody treatment and is due to enter phase I clinical trials later this year.

Mene Pangalos, executive vice president of AstraZeneca, said: “By combining our scientific expertise and sharing the risks and cost of development, we hope to accelerate the advancement of MEDI1341 as a promising new approach to support the treatment of people with Parkinson’s disease around the world.”

The two companies will share future development and commercialisation costs for MEDI1341 equally, in addition to future revenues.

Go Back

Share this story

Comments


Related articles


Women and Parkinson's

The women blazing the trail in Parkinson’s tech and innovation

Have you heard about these Parkinson’s technology inventions?

READ MORE
Michael J Fox webinar

Resources & Tools

WEBINAR: Learn about the role of intestinal bacteria in Parkinson’s disease

Register now for this free, hour-long live webinar

READ MORE

Perspectives

Who said what: QoTW 04.06.15

Our favourite quotes of the week from around the web

READ MORE